Comparative Pharmacology
Head-to-head clinical analysis: CLOMID versus FARESTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMID versus FARESTON.
CLOMID vs FARESTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (GnRH) and subsequent LH and FSH release, stimulating ovulation.
Selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptors, exerting antiestrogenic effects in breast tissue.
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
60 mg orally once daily.
None Documented
None Documented
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
The terminal elimination half-life of toremifene is approximately 5 days (range 2-10 days). The half-life of its main metabolite, N-desmethyltoremifene, is about 11 days. This long half-life supports once-daily dosing.
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
FARESTON (toremifene) is extensively metabolized in the liver. Excretion is primarily fecal (approximately 70%) with renal excretion accounting for less than 10% of the dose as unchanged drug and metabolites.
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator